Cramer Says Meta Is Not the New Tobacco, Warns Against Selling over Social Media Court Rulings

Why It Matters

The verdicts expose Meta to significant legal liability that could pressure valuation, yet Cramer’s bullish stance suggests fundamentals and AI investment may outweigh short‑term risk for investors.

Key Takeaways

• Two juries ordered $381M total damages against Meta.
• Shares fell >8% after verdicts, down 15% in March.
• Cramer calls Meta “not new tobacco,” urges buying dip.
• Forward P/E 18× versus five‑year average 23×.
• AI capex $115‑$135B planned despite legal headwinds.

Pulse Analysis

The recent jury decisions mark a rare challenge to Section 230 protections that have long insulated social‑media platforms from user‑generated content liability. By treating Meta’s apps as defective products, the California case sets a precedent that could embolden the more than 3,000 pending lawsuits across the state. While the $381 million total judgment is sizable, it represents a fraction of Meta’s revenue, and the company’s appeal strategy will be closely watched for any signals about broader regulatory exposure.

Market reaction has been swift: Meta’s shares tumbled over 8% on the day of the verdicts and have slipped roughly 15% in March, making it the laggard among megacap tech names. Cramer’s commentary frames this weakness as a contrarian entry point, emphasizing a forward price‑to‑earnings multiple of 18×, well below the five‑year average of 23×. The upcoming earnings report could either validate the discount or deepen concerns, especially if the company signals further cost cuts or additional legal provisions.

Strategically, Meta is doubling down on artificial‑intelligence infrastructure, earmarking $115‑$135 billion in capital expenditures for the year. This aggressive spend aims to cement its position in the AI race, offsetting short‑term headwinds from litigation and workforce reductions. Investors weighing the stock must balance the immediate legal risk against the long‑term upside of AI‑driven growth, a calculus that underpins Cramer’s “buy‑equivalent” rating and $825 price target.